Download PDF
Clin Colon Rectal Surg 2022; 35(06): 428-436
DOI: 10.1055/s-0042-1758048
Review Article

Medical Treatment Options for Ulcerative Colitis

Joseph Sleiman
1   Department of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
,
Mehak Bassi
2   Division of Gastroenterology and Hepatology, Saint Peter's University Hospital, Rutgers University, New Brunswick, New Jersey
,
Evangelos Tsipotis
3   Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia
,
Aline Charabaty
4   Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Maryland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

The landscape of management of ulcerative colitis, a type of inflammatory bowel disease, continues to change with advancement in pharmaceutical options as well as clinical treatment targets. Ulcerative colitis primarily involves the superficial layers of the large bowel, and cause active inflammation that can affect the colon from the rectum to the cecum in a relapsing and a remitting course. In this review, we provide evidence-based guidance on the selection of appropriate medical therapies based on individual patient and disease characteristics, with a focus on biologics and small molecules. We also review the role of surgery and management of acute severe ulcerative colitis.

Keywords

ulcerative colitis - biologics - inflammatory bowel disease - acute severe ulceration colitis


Publication History

Article published online:
09 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Shivashankar R, Tremaine WJ, Harmsen WS, Loftus Jr EV. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol 2017; 15 (06) 857-863
    CrossrefPubMedSearch in Google Scholar
  • 2 Safroneeva E, Vavricka S, Fournier N. et al; Swiss IBD Cohort Study Group. Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients. Aliment Pharmacol Ther 2015; 42 (05) 540-548
    CrossrefPubMedSearch in Google Scholar
  • 3 Turner D, Ricciuto A, Lewis A. et al; International Organization for the Study of IBD. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160 (05) 1570-1583
    CrossrefPubMedSearch in Google Scholar
  • 4 Sands BE, Peyrin-Biroulet L, Loftus Jr EV. et al; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381 (13) 1215-1226
    CrossrefPubMedSearch in Google Scholar
  • 5 Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017; 152 (02) 362-373.e3
    CrossrefPubMedSearch in Google Scholar
  • 6 Peyrin-Biroulet L, Sandborn W, Sands BE. et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110 (09) 1324-1338
    CrossrefPubMedSearch in Google Scholar
  • 7 Peyrin-Biroulet L, Panés J, Sandborn WJ. et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016; 14 (03) 348-354.e17
    CrossrefPubMedSearch in Google Scholar
  • 8 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114 (03) 384-413
    CrossrefPubMedSearch in Google Scholar
  • 9 Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology 2015; 149 (01) 238-245
    CrossrefPubMedSearch in Google Scholar
  • 10 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs 2015; 75 (08) 879-886
    CrossrefPubMedSearch in Google Scholar
  • 11 Mahadevan U, Long MD, Kane SV. et al; Crohn's Colitis Foundation Clinical Research Alliance. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 2021; 160 (04) 1131-1139
    Search in Google Scholar
  • 12 Gisbert JP, Linares PM, McNicholl AG, Maté J, Gomollón F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009; 30 (02) 126-137
    CrossrefPubMedSearch in Google Scholar
  • 13 Walker GJ, Harrison JW, Heap GA. et al; IBD Pharmacogenetics Study Group. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA 2019; 321 (08) 773-785
    CrossrefPubMedSearch in Google Scholar
  • 14 Dubinsky MC, Lamothe S, Yang HY. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118 (04) 705-713
    CrossrefPubMedSearch in Google Scholar
  • 15 Beaugerie L. Lymphoma: the bête noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease. Gastroenterology 2013; 145 (05) 927-930
    CrossrefPubMedSearch in Google Scholar
  • 16 Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L. Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD. Gut 2014; 63 (12) 1843-1853
    CrossrefPubMedSearch in Google Scholar
  • 17 Bourrier A, Carrat F, Colombel JF. et al; CESAME study group. Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Aliment Pharmacol Ther 2016; 43 (02) 252-261
    CrossrefPubMedSearch in Google Scholar
  • 18 Sandborn WJ, Feagan BG, Marano C. et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146 (01) 85-95 , quiz e14–e15
    CrossrefPubMedSearch in Google Scholar
  • 19 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142 (02) 257-65.e1 , 3
    CrossrefPubMedSearch in Google Scholar
  • 20 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353 (23) 2462-2476
    CrossrefPubMedSearch in Google Scholar
  • 21 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015; 11: 63-73
    PubMedSearch in Google Scholar
  • 22 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146 (02) 392-400.e3
    CrossrefPubMedSearch in Google Scholar
  • 23 Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2014; 20 (10) 1862-1869
    CrossrefPubMedSearch in Google Scholar
  • 24 Nielsen OH, Loftus Jr EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013; 11: 174
    CrossrefPubMedSearch in Google Scholar
  • 25 Hindryckx P, Vande Casteele N, Novak G. et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients?. J Crohn's Colitis 2018; 12 (01) 105-119
    CrossrefPubMedSearch in Google Scholar
  • 26 Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol 2011; 106 (12) 2146-2153
    CrossrefPubMedSearch in Google Scholar
  • 27 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7 (08) 874-881
    CrossrefPubMedSearch in Google Scholar
  • 28 DʼHaens G, Reinisch W, Panaccione R. et al. Lymphoma risk and overall safety profile of adalimumab in patients with Crohn's disease with up to 6 years of follow-up in the pyramid registry. Am J Gastroenterol 2018; 113 (06) 872-882
    CrossrefPubMedSearch in Google Scholar
  • 29 Nyboe Andersen N, Pasternak B, Basit S. et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA 2014; 311 (23) 2406-2413
    CrossrefPubMedSearch in Google Scholar
  • 30 Sazonovs A, Kennedy NA, Moutsianas L. et al; PANTS Consortium. HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn's disease. Gastroenterology 2020; 158 (01) 189-199
    CrossrefPubMedSearch in Google Scholar
  • 31 Kennedy NA, Heap GA, Green HD. et al; UK Inflammatory Bowel Disease Pharmacogenetics Study Group. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4 (05) 341-353
    CrossrefPubMedSearch in Google Scholar
  • 32 Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10 (10) 1079-1087 , quiz e85–e86
    CrossrefPubMedSearch in Google Scholar
  • 33 Ben-Horin S, Waterman M, Kopylov U. et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11 (04) 444-447
    CrossrefPubMedSearch in Google Scholar
  • 34 Yarur AJ, Kubiliun MJ, Czul F. et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13 (06) 1118-24.e3
    CrossrefPubMedSearch in Google Scholar
  • 35 Colombel JF, Sands BE, Rutgeerts P. et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66 (05) 839-851
    CrossrefPubMedSearch in Google Scholar
  • 36 Feagan BG, Rutgeerts P, Sands BE. et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369 (08) 699-710
    CrossrefPubMedSearch in Google Scholar
  • 37 Hu A, Kotze PG, Burgevin A. et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol 2021; 19 (07) 1366-1376.e2
    CrossrefPubMedSearch in Google Scholar
  • 38 Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019; 58 (Suppl. 01) i43-i54
    CrossrefPubMedSearch in Google Scholar
  • 39 Ytterberg SR, Bhatt DL, Mikuls TR. et al; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022; 386 (04) 316-326
    CrossrefPubMedSearch in Google Scholar
  • 40 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47 (02) 162-175
    CrossrefPubMedSearch in Google Scholar
  • 41 Sandborn WJ, Su C, Sands BE. et al; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376 (18) 1723-1736
    CrossrefPubMedSearch in Google Scholar
  • 42 Honap S, Chee D, Chapman TP. et al; LEO [London, Exeter, Oxford] IBD Research Consortium. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience. J Crohn's Colitis 2020; 14 (10) 1385-1393
    CrossrefPubMedSearch in Google Scholar
  • 43 Vermeire S, Su C, Lawendy N. et al. Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohn's Colitis 2021; 15 (07) 1130-1141
    CrossrefPubMedSearch in Google Scholar
  • 44 Sandborn WJ, Ghosh S, Panes J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020; 158 (08) 2139-2149.e14
    CrossrefPubMedSearch in Google Scholar
  • 45 Vermeire S, Danese S, Zhou W. et al. OP23 efficacy and safety of upadacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: results from phase 3 U-ACCOMPLISH study. J Crohn's Colitis 2021; 15 (Suppl. 01) S021-S022
    CrossrefPubMedSearch in Google Scholar
  • 46 Sands BE, Sandborn WJ, Panaccione R. et al; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381 (13) 1201-1214
    CrossrefPubMedSearch in Google Scholar
  • 47 Sandborn WJ, Feagan BG, D'Haens G. et al; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2021; 385 (14) 1280-1291
    CrossrefPubMedSearch in Google Scholar
  • 48 Edwards FCTS, Truelove SC. The course and prognosis of ulcerative colitis. Gut 1963; 4: 299-315
    CrossrefPubMedSearch in Google Scholar
  • 49 Dinesen LWalsh AJ, Protic MN. et al. The pattern and outcome of acute severe coliti. J Crohn's Colitis 2010; 4 (04) 431-437
    CrossrefPubMedSearch in Google Scholar
  • 50 Truelove SCWL. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2 (4884): 375-378
    CrossrefPubMedSearch in Google Scholar
  • 51 Feuerstein JDIK, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S. AGA Institute Clinical Guidelines Committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158 (05) 1450-1461
    CrossrefPubMedSearch in Google Scholar
  • 52 Järnerot G, Hertervig E, Friis-Liby I. et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128 (07) 1805-1811
    CrossrefPubMedSearch in Google Scholar
  • 53 Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94 (06) 1587-1592 . Doi: 10.1016/S0002-9270(99)00205-1
    CrossrefPubMedSearch in Google Scholar
  • 54 Christensen B, Gibson PR, Micic D. et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease. Clin Gastroenterol Hepatol 2019; 17 (03) 486-493
    CrossrefPubMedSearch in Google Scholar
  • 55 Berinstein JA, Sheehan JL, Dias M. et al. Tofacitinib for biologic-experienced hospitalized patients with acute severe ulcerative colitis: a retrospective case-control study. Clin Gastroenterol Hepatol 2021; 19 (10) 2112-2120.e1
    CrossrefPubMedSearch in Google Scholar
  • 56 Cacheux W, Seksik P, Lemann M. et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 2008; 103 (03) 637-642
    CrossrefPubMedSearch in Google Scholar
  • 57 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis?. Clin Gastroenterol Hepatol 2015; 13 (02) 336-338
    CrossrefPubMedSearch in Google Scholar
  • 58 Travis SPFJ, Farrant JM, Ricketts C. et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38 (06) 905-910
    CrossrefPubMedSearch in Google Scholar
  • 59 Moore AC, Bressler B. Acute severe ulcerative colitis: the Oxford criteria no longer predict in-hospital colectomy rates. Dig Dis Sci 2020; 65 (02) 576-580
    CrossrefPubMedSearch in Google Scholar
  • 60 Ho GTMC, Mowat C, Goddard CJ. et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19 (10) 1079-1087
    CrossrefPubMedSearch in Google Scholar